Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14259330 | 0.86 | CYP4F2 (0.59) | NLRP3CYP4F2CYP4A11ALDH1A1KDM4E | |
| SCHEMBL4920335 | 0.84 | KEAP1 (0.49) | EGFRPKMCYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL14259344 | 0.84 | MTNR1A (0.52) | ALDH1A1MAPTKDM4EL3MBTL1PPARG | |
| SCHEMBL905142 | 0.84 | CTBP2 (0.49) | EGFRPKMALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL68340 | 0.80 | PKM (0.60) | PKMNLRP3CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL6878047 | 0.77 | PKM (0.57) | PKMNLRP3CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL31424953 | 0.77 | PKM (0.57) | PKMNLRP3CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL31424955 | 0.77 | PKM (0.57) | PKMNLRP3CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL14259334 | 0.76 | TDP1 (0.51) | ALDH1A1MAPTKDM4EMEN1LMNA | |
| SCHEMBL10758204 | 0.76 | SMN1; SMN2 (0.46) | PKMCYP4F2CYP4A11ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064716-A1 | Alpha v beta 3 and/or alpha v beta 5 integrin inhibitors; osteoporosis, retinopathy, tumor metastasis and angiogenesis; decreased side effects, improved potency; 3-(2-(3-[2-(5,6,7,8- Tetrahydro-1,8-naphthyridin-2-yl)ethoxy]benzyl}-phenyl)propionic acid | PHARMACIA | 2008-03-13 | — | — | US | disclosed |
| US-20080064716-A1 | Alpha v beta 3 and/or alpha v beta 5 integrin inhibitors; osteoporosis, retinopathy, tumor metastasis and angiogenesis; decreased side effects, improved potency; 3-(2-(3-[2-(5,6,7,8- Tetrahydro-1,8-naphthyridin-2-yl)ethoxy]benzyl}-phenyl)propionic acid | PHARMACIA | 2008-03-13 | — | — | US | disclosed |
| US-20080064716-A1 | Alpha v beta 3 and/or alpha v beta 5 integrin inhibitors; osteoporosis, retinopathy, tumor metastasis and angiogenesis; decreased side effects, improved potency; 3-(2-(3-[2-(5,6,7,8- Tetrahydro-1,8-naphthyridin-2-yl)ethoxy]benzyl}-phenyl)propionic acid | PHARMACIA | 2008-03-13 | — | — | US | disclosed |
| EP-1802618-A1 | BIPHENYL INTEGRIN ANTAGONISTS | Pharmacia Corporation (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006043930-A1 | BIPHENYL INTEGRIN ANTAGONISTS | PHARMACIA CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064716-A1 | Alpha v beta 3 and/or alpha v beta 5 integrin inhibitors; osteoporosis, retinopathy, tumor metastasis and angiogenesis; decreased side effects, improved potency; 3-(2-(3-[2-(5,6,7,8- Tetrahydro-1,8-naphthyridin-2-yl)ethoxy]benzyl}-phenyl)propionic acid | ITGA5, ITGAV, ITGB5 | EGFR 695/4885PKM 2202/4885NLRP3 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.